MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Market Cap 2011-2026 | XGN
As of April 07, 2026 Exagen has a market cap of $ 66.4 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 70.1 M | 59.2 M | 31.3 M | 40.3 M | 121 M | 199 M | 80.5 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | 31.3 M | 85.9 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 168.22 | -3.26 % | $ 8.34 B |  USA |
 |
Agilent Technologies
A
|
42 B | $ 114.84 | -0.55 % | $ 34.9 B | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 24.73 | -0.44 % | $ 687 M | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 192.12 | 0.53 % | $ 137 B | USA |
 |
DexCom
DXCM
|
25.5 B | $ 63.21 | 1.59 % | $ 24.7 B | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
Guardant Health
GH
|
13.4 B | $ 89.66 | -4.44 % | $ 11.2 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 109.62 | -4.0 % | $ 9.04 B |  Irlanda |
 |
CareDx, Inc
CDNA
|
993 M | $ 17.82 | -2.68 % | $ 950 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 127.74 | 0.28 % | $ 20.3 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 16.3 | 0.62 % | $ 175 M |  China |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 170.72 | -1.47 % | $ 29.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 274.46 | 0.27 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 75.89 | -0.28 % | $ 5.12 B | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 496.0 | -0.47 % | $ 14.3 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 266.63 | 0.53 % | $ 26.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.67 | -1.68 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
3.66 M | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.02 | 0.25 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.56 | 1.59 % | $ 2.07 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
315 M | $ 17.33 | 0.99 % | $ 388 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 204.87 | -1.5 % | $ 20.2 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 15.36 | 1.92 % | $ 1.99 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.42 | 5.97 % | $ 426 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 27.2 | 0.33 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
38.4 M | $ 25.98 | 1.64 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
254 M | $ 6.58 | - | $ 390 M | USA |
 |
RadNet
RDNT
|
5.62 B | $ 55.06 | 0.49 % | $ 4.14 B | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 6.69 | -3.04 % | $ 279 M | USA |
 |
Sotera Health Company
SHC
|
4.75 B | $ 14.87 | -0.6 % | $ 4.22 B | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Soleno Therapeutics
SLNO
|
2.08 B | $ 52.25 | 32.31 % | $ 2.66 B | USA |
 |
Neuronetics
STIM
|
81.1 M | $ 1.76 | 15.79 % | $ 116 M | USA |
 |
Thermo Fisher Scientific
TMO
|
196 B | $ 488.19 | -0.67 % | $ 184 B | USA |